Experimental Alzheimer’s Drug Failure ‘Heartbreaking’
Drug manufacturer Eli Lilly announced in November 2016 that its trial of a drug known as solanezumab failed to live up to its hoped for promise of slowing the progression of memory loss and confused thinking. The clinical trial began after solanezumab had already been shown to be ineffective against mild or moderate Alzheimer’s disease…
View Article